333 related articles for article (PubMed ID: 15338762)
1. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
2. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
[TBL] [Abstract][Full Text] [Related]
3. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
4. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?
Zedenius J
Acta Oncol; 2008; 47(1):3-4. PubMed ID: 17891671
[No Abstract] [Full Text] [Related]
6. Established clinical use of octreotide and lanreotide in oncology.
Oberg K
Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
[TBL] [Abstract][Full Text] [Related]
7. Role of Somatostatin Analogues in Oncology. European Neuroendocrine Tumor Network (ENET). February 24-27, 2000, Innsbruck, Austria. Proceedings.
Digestion; 2000; 62 Suppl 1():1-108. PubMed ID: 11001649
[No Abstract] [Full Text] [Related]
8. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.
Pivonello R; Ferone D; Filippella M; Faggiano A; De Martino MC; Auriemma RS; Rota F; Lombardi G; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):82-8. PubMed ID: 15233220
[No Abstract] [Full Text] [Related]
9. The role of somatostatin analogs in the management of prostate cancer.
Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
[No Abstract] [Full Text] [Related]
10. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
11. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
Oberg KE
J Clin Oncol; 2009 Oct; 27(28):4635-6. PubMed ID: 19704053
[No Abstract] [Full Text] [Related]
12. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).
Oberg K
Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941
[No Abstract] [Full Text] [Related]
15. Antitumor effect of somatostatin analogs in neuroendocrine tumors.
Chua YJ; Michael M; Zalcberg JR; Hicks RJ; Goldstein D; Liauw W; Price T
J Clin Oncol; 2010 Jan; 28(3):e41-2; author reply e43-4. PubMed ID: 20008618
[No Abstract] [Full Text] [Related]
16. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
17. Commentary: Somatostatin analogs-How we choose, and why.
Reidy-Lagunes D; Raj N; Saltz L
Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
[No Abstract] [Full Text] [Related]
18. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
19. The role of angiogenesis in neuroendocrine tumors.
Lyons J; Anthony CT; Woltering EA
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):839-52. PubMed ID: 21095549
[TBL] [Abstract][Full Text] [Related]
20. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
